Cerebral Venous Sinus Thrombosis Linked to Hepatic Dysfunction & Viral Hepatitis: A Clinical Case Study
Cerebral Venous Sinus Thrombosis in the Setting of Hepatic Dysfunction and Viral Hepatitis Seropositivity: A Case Report
Patients with concurrent hepatic dysfunction and viral hepatitis seropositivity face heightened risks of cerebral venous sinus thrombosis (CVST), according to a case report published in *Cureus* on June 15, 2026. The study details a 47-year-old male with a history of chronic hepatitis B and elevated liver enzymes who presented with acute headaches and visual disturbances, later diagnosed with CVST via cerebral venography.
Key Clinical Takeaways:
- CVST incidence rises in patients with hepatic dysfunction due to altered coagulation profiles and chronic inflammation.
- Viral hepatitis seropositivity may amplify thrombotic risk through hepatic enzyme dysregulation and immune activation.
- Early diagnosis via imaging and targeted anticoagulation improves outcomes in complex cases.
Case Presentation and Clinical Context
The patient, initially diagnosed with hepatitis B in 2018, had a history of elevated alanine aminotransferase (ALT) levels exceeding 150 U/L. His recent laboratory results showed international normalized ratio (INR) of 1.8 and platelet count of 120,000/µL. Neurological symptoms emerged over three days, prompting MRI with venography, which revealed thrombosis in the transverse and sigmoid sinuses. According to the *Cureus* case report, the diagnosis was confirmed via contrast-enhanced CT angiography.
Dr. Emily Zhang, a hematologist at the University of California, San Francisco, noted, “Hepatic dysfunction disrupts vitamin K-dependent clotting factors, creating a prothrombotic state. Viral hepatitis further complicates this by inducing systemic inflammation and liver fibrosis, which may predispose to cerebral venous thrombosis.”
Pathogenesis and Risk Factors
CVST occurs in approximately 1 in 100,000 adults annually, but its incidence increases in patients with underlying liver disease. A 2023 *Journal of Neurology* study found that hepatic dysfunction correlates with a 3.2-fold higher risk of CVST, particularly in those with cirrhosis or chronic viral hepatitis. The interplay between viral hepatitis and coagulopathy is multifactorial: hepatitis B virus (HBV) induces proinflammatory cytokines, while impaired liver function reduces antithrombin III synthesis, a key anticoagulant.
Dr. Raj Patel, a hepatologist at the Mayo Clinic, emphasized, “The liver’s role in producing clotting factors and metabolizing anticoagulants means even mild dysfunction can tip the balance toward thrombosis. In our clinic, we now screen hepatitis patients for neurological symptoms more aggressively.”
Therapeutic Implications and Management
The patient received initial treatment with low-molecular-weight heparin (LMWH) followed by warfarin, with INR monitored to maintain 2–3. His symptoms resolved within two weeks, and follow-up imaging showed partial recanalization of the affected sinuses. The *Cureus* report highlights the importance of individualized anticoagulation strategies in patients with comorbid liver disease.
However, anticoagulation in hepatic dysfunction carries risks. A 2021 *New England Journal of Medicine* review noted that liver disease patients on warfarin have a 20% higher risk of bleeding complications compared to the general population. “We often use direct oral anticoagulants (DOACs) when feasible,” said Dr. Zhang. “But their safety in severe hepatic impairment remains under study.”
Public Health and Diagnostic Considerations
The case underscores the need for heightened vigilance in viral hepatitis carriers. The World Health Organization (WHO) estimates 296 million people globally are living with chronic hepatitis B, with 1.1 million deaths annually from related complications. Early recognition of CVST in this population could prevent severe morbidity, including seizures, visual loss, and intracranial hemorrhage.
Dr. Patel added, “Clinicians should consider CVST in any hepatitis patient presenting with new-onset headaches, especially if imaging is accessible. [Relevant Clinic/Professional/Service] offers specialized neuro-vascular imaging protocols for such cases.”
Future Research and Clinical Guidelines
While the *Cureus* case report is a single instance, it aligns with broader trends. A 2025 *Lancet Gastroenterology & Hepatology* meta-analysis found that viral hepatitis patients had a 2.7-fold increased risk of thromboembolic events, with CVST being a rare but critical subset. The study authors called for standardized screening protocols and further research into mechanistic links between hepatic dysfunction and cerebral thrombosis.
For healthcare providers managing patients with liver disease, the case reinforces the importance of multidisciplinary care. [Relevant Clinic/Professional/Service] specializes in integrating hepatology and neurology services, offering comprehensive management for complex cases.
Editorial Kicker
This case report serves as a critical reminder of the interconnectedness of systemic health. As diagnostic tools advance and liver disease prevalence rises, clinicians must remain attuned to atypical presentations. The integration of specialized care models, such as those offered by [Relevant Clinic/Professional/Service], may prove vital in addressing these challenges.
Disclaimer: The information provided in this article is for educational and scientific communication purposes